RecruitingNCT06726200
Injectable and under-the-tongue buprenorphine for people who use fentanyl
About this title
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
Read the official source — NCT06726200Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 25, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Rachel R. Luba
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- EARLY Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06726200
- Official title
Show the full official title
A Randomized Controlled Trial Examining Extended-Release Injectable Buprenorphine in Those Who Use High Potency Synthetic Opioids
Recruitment & locations
RecruitingNew York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Rachel R. Luba.
Does this study involve medication?
Yes. The study involves medication, including Buprenorphine + naloxone (Suboxone) and Buprenorphine Injection.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
